Spain RUO Immunoassay market is projected to grow at a CAGR of 9.68% from 2025 to 2030.
The RUO immunoassay demand in Spain is witnessing robust growth owing to several factors such as aging population and a strong research sector. Spain is also witnessing a staggering rise in chronic ailments like diabetes, it was 5,141.3 (in 000s) in 2021, predicted to be 5,576.0 in 2030, and 5,647.6 in 2045. Further, the impact of cardiovascular diseases is on the rise in Spain, which led to the development of the National Health System approving the Cardiovascular Health Strategy in 2022. Due to these factors, Spain spends a significant amount on pharmaceutical industry research and development about which was about €1,267 million in 2021.
RUO immunoassays can be used to detect a wide range of biomarkers for chronic diseases. RUO immunoassays are becoming increasingly accurate for use in various research and development purposes. The widespread use of these immunoassays is expected to grow significantly in the coming years, due to increasing demand for affordable and accurate tools.
Biopharma's consumption in Spain rose by 8%, which was significantly lower than the 19.4% increase in production. In the year 2022, Spain imported €9,581 million medicinal and pharmaceutical products and exported €8,256 million. Leading companies such as Werfen in the country specialize in developing and manufacturing biomaterials for AMH immunoassay development. They provide antibody-like proteins used in the production of immunoassays for AMH determination. Moreover, these companies have extensive experience in IVD immunoassay development and manufacturing, allowing them to address the challenges faced by immunoassay manufacturers and prioritize critical factors in biomaterial production to ensure robustness. Further, they use high throughput technologies that allow to test more experimental conditions efficiently, thus reducing the risks.
Another significant company is Grifols, S.A., which has expertise in biological drug monitoring, they offer a wide range of tests as ELISA assays and mono tests for any laboratory workflow. In March 2022, Araclon Biotech, part of the Grifols Group and focused on researching and developing therapies and diagnostic approaches for Alzheimer's disease (AD), achieved CE marking for its two early-stage diagnostic tests. Both tests utilize mass spectrometry (ABtest-MS) and ELISA (ABtest-IA) to quantify Aβ40 and Aβ42 proteins, which are linked to AD risk, in biological samples such as plasma. These tests offer a rapid, reliable, and minimally invasive method for diagnosing AD, with lower costs compared to other methods. Moreover, utilizing these plasma tests as pre-screening tools could significantly reduce the recruitment costs for clinical trials of new AD treatments.
| Report Metric | Details |
|---|---|
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Report Metric | Details |
| Growth Rate | CAGR of 9.68% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Forecast Unit (Value) | USD Billion |
| Segmentation |
|
| Geographical Segmentation | Madrid, Catalonia, Andalusia, Valencian Community, Galicia |
| List of Major Companies in the Spain RUO Immunoassay Market | |
| Customization Scope | Free report customization with purchase |
Spain RUO Immunoassay Market Segmentations:
By Product Type
By Sample Type
By Application
By End-User
By Province